Omalizumab in chronic spontaneous urticaria: a real-life experience of dose and intervals adjustments in Belgium

Omalizumab was clearly shown to be effective and safe for treating refractory chronic spontaneous urticaria (CSU) not adequately controlled with H1-antihistamines (anti-H1). Supported by data of five randomized, placebo-controlled clinical trials,1 the recommended regimen is 300mg every four weeks, 38.1%/55.1% of patients being respectively completely/partially free of urticaria after 12 weeks with this regimen.

https://ift.tt/2NtyuJ7